Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia
Continuous treatment with ibrutinib not only exerts tumor control but also enhances T cell function in patients with chronic lymphocytic leukemia (CLL). We conducted longitudinal multi-omics analyses in samples from CLL patients receiving ibrutinib upfront to identify potential adaptive mechanisms...
Saved in:
| Main Authors: | Daniel Medina-Gil, Laura Palomo, Víctor Navarro, Gonzalo Lázaro, Beatriz Martín-Mur, Cristina Hernández, Oriol Castells, Belén Sánchez, Pau Marc Muñoz-Torres, Carlota Pagès, Gemma Pujadas, Anna Esteve-Codina, Alba Cabirta, Christelle Ferrà, Miguel Alcoceba, Maria José Terol, Rafael Andreu, Mercè Martí, Pau Abrisqueta, Francesc Bosch, Marta Crespo, Spanish Group of Chronic Lymphocytic Leukemia - GELLC |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-03-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11975 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Atypical course of COVID-19 in patient with Bruton agammaglobulinemia
by: Ivana Milošević, et al.
Published: (2020-11-01) -
Transient constrictive pericarditis in Bruton disease: a case report
by: S. V. Kruchinova, et al.
Published: (2024-06-01) -
Bruton’s Tyrosine Kinase: A Double-Edged Sword in Cancer and Aging
by: Zahraa Qusairy, et al.
Published: (2025-05-01) -
The Potential Therapeutic Role of Bruton Tyrosine Kinase Inhibition in Neurodegenerative Diseases
by: Francesco D’Egidio, et al.
Published: (2025-07-01) -
The role of microglia in multiple sclerosis: implications for treatment with Bruton’s tyrosine kinase inhibitors
by: Patrick Vermersch, et al.
Published: (2025-05-01)